Logo

GPCR

Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc. • NASDAQ
$35.81 ▲ 4.65% (+1.59)
Market Cap $2.06 B
52w High $40.29
52w Low $13.22
Dividend Yield 0%
P/E -9.78
Volume 480.88K
Outstanding Shares 57.57M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $73.787M ▲ $-65.712M ▼ 0% $-1.11 ▼ $-65.313M ▲
Q2-2025 $0 $70.451M ▲ $-61.661M ▼ 0% $-1.08 ▼ $-70.16M ▼
Q1-2025 $0 $56.311M ▲ $-46.833M ▼ 0% $-0.81 ▼ $-56.037M ▼
Q4-2024 $0 $47.061M ▲ $-36.479M ▼ 0% $-0.63 ▼ $-46.788M ▼
Q3-2024 $0 $45.836M $-33.977M 0% $-0.6 $-45.571M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $799.043M ▲ $832.159M ▲ $62.14M ▲ $770.019M ▼
Q2-2025 $786.496M ▼ $816.443M ▼ $44.362M ▲ $772.081M ▼
Q1-2025 $836.882M ▼ $866.549M ▼ $41.911M ▲ $824.638M ▼
Q4-2024 $883.518M ▼ $903.33M ▼ $38.487M ▲ $864.843M ▼
Q3-2024 $915.286M $933.217M $36.416M $896.801M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-65.712M ▼ $-50.996M ▲ $-49.319M ▼ $56.203M ▲ $-44.112M ▼ $-52.568M ▲
Q2-2025 $-61.661M ▼ $-54.558M ▼ $48.942M ▲ $517K ▼ $-5.099M ▲ $-54.79M ▼
Q1-2025 $-46.833M ▼ $-52.229M ▼ $34.033M ▲ $809K ▲ $-17.387M ▼ $-52.543M ▼
Q4-2024 $-36.479M ▼ $-36.467M ▼ $33.232M ▲ $615K ▲ $-2.62M ▲ $-36.483M ▼
Q3-2024 $-33.977M $-19.696M $-189.044M $-757K $-209.497M $-20.381M

Five-Year Company Overview

Income Statement

Income Statement Structure Therapeutics is still a pure research-stage company, so it has essentially no product revenue yet. The income statement is driven almost entirely by research and development and general operating costs. Losses have grown over time as the company has advanced more drug candidates into the clinic and expanded its team. This pattern is typical for an early-stage biotech: the focus is on building long‑term scientific value rather than near‑term profitability. The business will likely remain loss‑making until it either secures substantial partnership income or brings a product to market, both of which are uncertain and depend on clinical success.

Balance Sheet

Balance Sheet The balance sheet shows a young company that has scaled up quickly after its IPO. Total assets and cash have increased meaningfully, funded mostly by new equity rather than borrowing. Debt is minimal, which reduces financial strain and interest costs but means shareholders bear most of the risk through dilution. Reported cash and investments provide a sizeable financial cushion, suggesting the company can fund its research plans for several years if spending stays on its current trajectory. At the same time, the asset base is dominated by cash and intangibles, not hard assets, so long‑term value is highly dependent on the success of the drug pipeline rather than physical infrastructure.

Cash Flow

Cash Flow Cash flow reflects a classic clinical‑stage biotech profile: steady cash outflows from operations and negative free cash flow, with very little spent on physical assets or equipment. Most cash usage relates to research activities, clinical trials, and building the organization. There is effectively no cash coming in from product sales yet, so the company depends on past and future financing to support its burn rate. Management currently appears to have secured enough cash to pursue key milestones over the next few years, but delays, trial setbacks, or program expansions could increase funding needs over time. The central cash‑flow risk is whether clinical progress justifies continued investment before the current cash runway is exhausted.

Competitive Edge

Competitive Edge Competitively, Structure Therapeutics targets a very attractive but crowded space: oral treatments for obesity and other chronic diseases that are currently dominated by injectable drugs. Its main advantage is a specialized platform for designing oral small molecules against GPCR targets, which could offer more convenient and potentially cheaper alternatives to injections. Strong intellectual property, a focused technology niche, and an experienced scientific team strengthen its position. However, it faces intense competition from large pharmaceutical companies with deep resources and established obesity brands, as well as rival oral GLP‑1 programs. To carve out a durable position, its drugs will likely need to show clearly competitive weight loss, safety, and tolerability, and then be backed by strong partnering or commercial execution. Until late‑stage data arrive, its competitive strength remains promising but unproven.

Innovation and R&D

Innovation and R&D Innovation and R&D are the heart of this company. It is built around advanced structure‑based design of small molecules that act on GPCRs, allowing it to pursue oral versions of drug classes that have traditionally required injections. The lead obesity candidate, an oral GLP‑1 agonist, has already shown encouraging early weight‑loss and tolerability data, while additional programs in amylin agonists, muscle‑sparing weight loss, and idiopathic pulmonary fibrosis broaden the pipeline. The strategy clearly leans into combination therapies over time, using multiple oral agents to tackle complex metabolic diseases. This creates significant upside potential but also substantial scientific and development risk: most assets are still in early‑ to mid‑stage trials, where failure rates are high. Overall, R&D intensity is high, the platform appears differentiated, and the pipeline is becoming more diversified, which helps spread but does not eliminate risk.

Summary

Overall, Structure Therapeutics is a classic high‑risk, high‑potential clinical‑stage biotech. Financially, it is pre‑revenue, running deliberate operating losses and negative cash flow as it invests heavily in its pipeline, but it currently benefits from a strong cash position and minimal debt. Strategically, it is going after a massive opportunity in obesity and related diseases by trying to convert injectable success stories into convenient oral therapies, supported by a specialized GPCR‑focused discovery engine. The main potential upside lies in successful late‑stage data for its lead oral GLP‑1 program and the advancement of follow‑on obesity and pulmonary candidates. The main risks center on clinical trial outcomes, safety and efficacy versus powerful competitors, regulatory uncertainty, and the eventual need for additional capital if timelines stretch. Future developments in trial results, partnership deals, and cash burn will be key signposts for how the risk‑reward balance evolves.

NEWS

November 6, 2025 · 4:01 PM UTC

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Read more